Human Pluripotent Stem Cells (hPSCs) are particularly prone to developing abnormalities during their time in culture. In 5 passages or less, the variants that appear can rapidly become predominant, compromising your research work.
Traditional G-Banding karyotyping is helpful in providing an exhaustive structural and numerical variant analysis. However, it does not have the required sensitivity to identify the most frequent genomic defects in human pluripotent stem cells.
Additionally, hPSC research scientists need assays designed for in-process testing every 5-10 passages (Assou et al., 2020; McIntire et al., 2020; Pamies et al., 2017) in order to pick up abnormalities as early as possible in their workflow, and G-Banding is not designed to support that level of frequency in testing.
The sensitivity and speed required in delivering a reliable assessment of genomic stability in hPSCs led Stem Genomics to develop the iCS-digital™ PSC range.
Thanks to the high level of performance offered by digital PCR (200 bp and 20% mosaicism) combined with an in-depth analysis of most recurrent abnormalities in hPSCs (see SMART database), the iCS-digital™ PSC range of tests can detect sub-karyotyping abnormalities that G-Banding would miss.
ESCs & iPSCs
In-process control during cell amplification & maintenance
Cells in fresh culture media (or in cell culture supernatant)
Test with 24 probes: 92% of recurrent abnormalities
Test with 12 probes: 77.5% of recurrent abnormalities
Test the 20q11.21 region: the most common genomic abnormality in hPSCs (>20%)
>20% (depending on sample quality)
2-3 days after sample reception
Available as a service
(from one sample) or a kit:
Recommended guidelines in terms of genomic stability advise checking the cells every 5-10 passages during their time in culture, but also screening clones after any stressing process (reprogramming, gene editing, etc.) and during banking. It is also advisable when a new line is acquired.
Click on the graph for more details:
In order to accurately target the abnormalities relevant for hPSC researchers, Stem Genomics specifically analysed the data from +100 scientific publications concerning +900 hPSC samples. After exclusion of polymorphic variants, we highlighted the presence of 738 recurrent genetic abnormalities (i.e., genomic defects found in at least five different publications).
We then used these data to develop the iCS-digital™ PSC test.
Please enter your e-mail address.